Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas

NCT07843147 | Not Yet Recruiting

• 1 other identifier: 2026-03261
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Adult patients under investigation, follow-up, or treatment for benign or malignant pancreatic/periampullary conditions are invited to participate in either or both parts of the study.

Conditions

Pancreatic Neoplasms; Pancreatic Cysts; Hyperglycemia; Prediabetes

Keywords

continuous glucose monitoring; gut microbiota; pancreatic cancer; biomarker; fecal microbiome

Outcome Measures

Primary Outcomes (2)

• Difference in CGM-derived glycemic variability metrics

  14 days CGM recording period

• Difference in gut microbiota composition

  Single fecal sample

Study Arms (2)

Patients with pancreatic cancer

Patients with cysts or other benign pancreatic disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of consecutive adult patients evaluated or treated for pancreatic or periampullary diseases at the Department of Surgery/Cancer Center, Umeå University Hospital, Sweden.

You may qualify if:

• Adults (≥18 years of age).
• Undergoing clinical investigation, follow-up, or treatment for a pancreatic or periampullary condition (malignant or benign/premalignant, including cystic lesions and pancreatitis).
• Willing and able to provide written informed consent for participation in at least one component of the study (continuous glucose monitoring and/or fecal sample collection).

Sponsors & Collaborators

• Umeå University: lead
• Region Västerbotten: collaborator

Biospecimen

Retention: SAMPLES WITHOUT DNA

Fecal sample for gut microbiota metagenomic sequencing

MeSH Terms

Conditions

Pancreatic Neoplasms; Pancreatic Cyst; Hyperglycemia; Prediabetic State

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Cysts; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Diabetes Mellitus

Study Officials

• Oskar Franklin, M.D, PhD

  Umeå University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Oskar Franklin, M.D, PhD

CONTACT

+46 90 7865000; oskar.franklin@umu.se

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2026
• First Posted: September 25, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2029
• Study Completion (Estimated): October 1, 2031
• Last Updated: September 25, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share